A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous Abatacept in Adults With Active Primary Sjögrens Syndrome

Trial Profile

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous Abatacept in Adults With Active Primary Sjögrens Syndrome

Recruiting
Phase of Trial: Phase III

Latest Information Update: 14 Dec 2017

At a glance

  • Drugs Abatacept (Primary)
  • Indications Sjogren's syndrome
  • Focus Registrational; Therapeutic Use
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 17 Oct 2017 Planned End Date changed from 7 Aug 2021 to 5 Nov 2019.
    • 17 Oct 2017 Planned primary completion date changed from 18 Sep 2019 to 11 Nov 2018.
    • 09 Aug 2017 Planned End Date changed from 11 Aug 2021 to 7 Aug 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top